White House moves to put NIH grant decisions under political control

The White House is planning to hand veto power over National Institutes of Health grants to a political appointee². The move came from Russell Vought, head of the Office of Management and Budget, which has sought to limit and control research funds². STAT reported that Vought pushed for an executive order creating a commission that would review NIH grants⁴. Fierce Biotech reported the plan as putting NIH grants under political control⁷.

Science reported that the move to seize control of NIH grant decisions has upset senators and scientists, and that the budget chief reportedly wants more power to veto funding he regards as related to diversity, equity and inclusion⁵. Newsweek reported that Vought led criticism of the agency, arguing it had funded what he called woke initiatives⁶.

The pushback

Congressional leaders have warned the White House against adding controls over NIH grants¹. Senators Susan Collins and Patty Murray spoke out against what they described as a push to politicize grantmaking³. Vought and other officials met with them, and the senators pressed the budget office to quickly disburse NIH funds that they said had been delayed¹.

Collins’ objection carries an electoral edge: Newsweek reported her warning to the president against the NIH grant plan as polls show a tight race in Maine⁶. The senators’ complaint about delayed disbursement matters as much as the veto proposal, because money already appropriated and not released is a control mechanism that needs no executive order at all¹.

Why it matters to investors

Federal biomedical funding is the demand floor beneath university research, early-stage biotech and the laboratory supply chain. A political veto inserted into grant approval does not necessarily reduce the total appropriated, but it lengthens and randomises the timing of awards, and timing is what research budgets and supplier order books run on^2,4.

The delayed-disbursement complaint is the near-term signal to track, because it shows the constraint is already operating before any order is signed¹. The second is whether the order is issued at all, or whether congressional opposition from within the president’s own party stalls it^3,6. The third is the scope of the review commission: a body that screens a narrow category of awards is a different proposition from one that sits over the whole grant pipeline^4,5.